Conference Coverage

VIDEO: Keeping the Alzheimer’s big picture in mind as antiamyloid trials continue


 

AT AAIC 2015

WASHINGTON – Amyloid-beta has been the Alzheimer’s research darling for more than a decade, and finally, after many failures, some small successes may be appearing in antiamyloid trials.

Experts suggest that these encouraging early results may lead companies to retest failed drugs under new conditions – for example, by using patients who test positive for amyloid-beta on brain PET scans, who have prodromal disease, or who are asymptomatic.

But questions remain, and some are fundamental. The functional nature of amyloid remains unknown. There are still questions about which form is the most neurotoxic. Little is understood about the way it interacts with tau as symptoms emerge.

Will these lines of investigation fall to the wayside if companies and amyloid-centric researchers put too many eggs into the antiamyloid basket? Dr. Michael Wolfe, Ph.D., of Brigham and Women’s Hospital, Boston, discusses these issues in an interview.

msullivan@frontlinemedcom.com

On Twitter @alz_gal

Recommended Reading

Hormone therapy helps mood, but not cognition, in younger menopausal women
MDedge Internal Medicine
Cognitive impairment signals subclinical vascular disease
MDedge Internal Medicine
Mixed pathologies are very common in black Alzheimer’s patients
MDedge Internal Medicine
AAIC: Sedentary early adulthood may mean worse cognitive functioning later
MDedge Internal Medicine
VIDEO: Dementia risk doubled in type 1 diabetes patients
MDedge Internal Medicine
VIDEO: Investigating the role of plasmalogens in Alzheimer’s disease
MDedge Internal Medicine
Estrogen therapy linked to brain atrophy in women with diabetes
MDedge Internal Medicine
VIDEO: Postoperative cognitive decline hits women hardest
MDedge Internal Medicine
Biogen’s aducanumab stumbles on cognitive endpoints at 6 mg/kg dose
MDedge Internal Medicine
VIDEO: Alzheimer’s disease drug development targets disease modification
MDedge Internal Medicine